Esteve Brand Guidelines: A 1929 Manresa Pharmacy That Became a Barcelona Specialty Drug Maker

Vitamins made behind the counter.

Esteve did not start in Barcelona. Catalan and Spanish Wikipedia both say the company was born in Manresa, an inland Catalan town, in 1929, when Antoni Esteve i Subirana, a doctor of pharmacy from a long line of pharmacists, took over a pharmacy there and began selling his first vitamin preparations, made in the pharmacy itself. The German trade paper Apotheke Adhoc also gave 1929 as the founding year in May 2023.

In 1936 the business was incorporated as a public limited company, Laboratorios del Dr. Esteve, S.A., according to the Wikipedia timelines. It moved to Barcelona in 1942, after the Spanish Civil War, and built new laboratories in the Guinardó district; Spanish Wikipedia records a visit to those laboratories by Alexander Fleming in 1948. The founder’s children later continued the business, and the family still controls it.

The post-war decades brought new arms. A veterinary division was created in 1963 and Esteve Química, making active pharmaceutical ingredients, in 1966. In 1971 the company put on the Spanish market a vascular medicine from its own research, calcium dobesilate, sold as Doxium, which the Wikipedia timelines say was later sold in some 80 countries. A hospital division followed in 1989, a plant in Mexico and a Portuguese subsidiary in 1992.

From Isdin to specialty medicines.

One of the names linked to Esteve is a joint venture. In 1974 it created Isdin with the perfumery group Antonio Puig, the Wikipedia timelines say, and Apotheke Adhoc described Isdin in 2023 as a joint venture with the Spanish cosmetics maker Puig. Esteve also set up a joint venture in China with Zhejiang Huayi Pharmaceutical in 2000, opened a representative office in New Jersey in 2007, and in 2006 joined Almirall, Ferrer, Uriach and others in a Catalan research consortium called Genius Pharma.

PharmaBoardroom described Esteve in 2023 as a family-owned mid-sized company that had long been firmly rooted in Spain. Its shape changed after 2018, when, English Wikipedia says, it appointed its first chief executive from outside the family. The same July 2023 report said Esteve had redefined its strategy in 2018 and had since sold its generics division, in 2019, and bought the German company Riemser, in 2020. Apotheke Adhoc gives the same sequence: the generics arm, which traded as Pensa, was sold in 2019, and Riemser, based in Greifswald and Berlin, was bought from the investor Ardian early in 2020. Esteve says Riemser became Esteve Pharmaceuticals GmbH in November 2021, and that its British business, Intrapharm, was renamed Esteve UK in April 2022.

Acquisitions have continued. In July 2024 the company said it had completed the purchase of HRA Pharma Rare Diseases from Perrigo, adding three medicines for Cushing’s syndrome and adrenocortical carcinoma; in July 2025 it bought Regis Technologies, a Chicago contract manufacturer; and in January 2026 it agreed to buy TerSera Therapeutics’ infusion specialty therapies unit, a deal it said in April 2026 had closed in March. In January 2026 Esteve announced that it had been certified as a B Corp.

How mid-sized drug makers present themselves.

Europe’s mid-sized drug makers tend to present themselves through their origins. Many began as a single pharmacist, doctor or industrialist with a laboratory, and their corporate histories still open with a founder, a town and a first product. Family holding companies and foundations often remain in the background as long-term shareholders, and the companies’ own timelines give as much space to new factories and research centres as to the medicines that came out of them.

The visual language that follows is restrained. Corporate sites and annual reports favour photographs of scientists at the bench, production lines seen through glass, and patients in ordinary settings — at home, at work, outdoors — rather than in hospital. Long-serving research campuses, some in use for half a century or more, appear again and again as proof of continuity, alongside newer laboratories in biotech districts abroad.

Identity systems are usually simple: a short word mark or set of initials, a single deep blue or green as the lead colour, and a clean sans for running text. Because prescription medicines cannot be advertised to the general public in the European Union, much of the visible branding lives at medical congresses rather than in shop windows: the dermatology meeting of the EADV, the multiple sclerosis congress of ECTRIMS and the reproductive-medicine meeting of ESHRE are among the places where these companies set up stands, posters and symposia for specialists.

This guide sets out what can be checked about each company — who founded it, who owns it, where it makes and researches its medicines, and how its history is told — and marks plainly what rests only on the company’s own word. The palettes and typefaces shown here are our own interpretations, not official brand assets.

A family company with a German partner.

Esteve calls itself a privately owned, international specialty pharmaceutical company with its head office in Barcelona. In May 2023 it brought in an outside shareholder. Apotheke Adhoc reported on 22 May 2023 that Lubea, an investment company based in Norderstedt in northern Germany, was taking a minority stake of 26%, and that Grupo Esteve Lifesciences, the holding behind the founding family, would remain the main shareholder, with the organisation unchanged. The same report said the deal still needed approval from the European competition authorities.

The family is still on the board. The company’s governance page names Albert Esteve as chairman of a thirteen-member board that also includes Jordi Esteve, while the chief executive is Staffan Schüberg. The executive team runs two businesses side by side: a pharma business with affiliates in Spain, Germany, France, the United Kingdom, Portugal, Italy, Austria and the United States, and a contract development and manufacturing business that makes active ingredients for other drug makers.

That second business has deep local roots. Catalan Wikipedia lists finished-product plants at Martorelles and ingredient plants at Celrà, near Girona, and Banyeres del Penedès; the company says it also has industrial sites in Mexico and China. In June 2024 Esteve announced a new plant at its Celrà centre, and in March 2026 it said it would add spray dryers there and launched a new brand for the manufacturing business. The company said in January 2026 that about 2,000 people work for it.

For a design guide, Esteve shows how a pharmacy-born family firm can rebuild itself as an international specialty company without changing its name. Compare Almirall, another Barcelona drug maker that took part in Genius Pharma, and Pierre Fabre, which also grew out of a pharmacy. For this guide we use a harbour slate, a terracotta and a warm sand with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Esteve’s identity on hand — save it to a board in the Made Good inspiration library.